Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) currently has a daily average trading volume of 276.46K but it saw 448132 shares traded on Wednesday. With a market cap of 217.20M USD, stock’s current market price of $4.51 came rising about 7.13 while comparing to the previous closing price of $4.21. In past 52 weeks, the stock remained buoying in the range of price level as high as $13.15 and as low as $3.97. In the recent trading on the day, stock has struck highest price mark of $4.69 while lowest mark touched by it was $4.18.
Taking a look at 20-day trading activity of Marinus Pharmaceuticals Inc. (MRNS) gives us an average price of $5.03, while its current price level is -65.70% below from 52-week high level whereas it is 13.60% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $5.74 while that of 200 days or SMA-200 reads an average of $6.56. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.58% during that period while stretching the period over a month that increases to 7.23%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 38.29 which implies that the stock is in neutral territory.
Marinus Pharmaceuticals Inc. (MRNS)’s stock is currently under the radar of 10 analysts who are in consensus at a 12-month price target range of between $12.00 and $50.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $12.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $50.00. Average price target assigned by them is $25.11 which highlights an upside potential of 82.04% for the stock over that period. And to attain the median price target of $24.00 assigned by those analysts, stock has to add about 81.21% of value to its current levels.
Data by FactSet Research shows that 10 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 1 are advising it as an Overweight. 9 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Strong Buy.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Truist which initiated the stock as “Buy” in its note to investors issued on September 30, 2020, recommending a price target of $35 for it.
Over the week, MRNS’s stock price is moving -1.96% down while it is -7.01% when we observe its performance for the past one month. Year-to-date it is -62.04% down and over the past year, the stock is showing a downside performance of -61.58%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2022, when its quarterly earnings per share (EPS) of -$1.06 beaten by the consensus estimate of -$0.68 for the same. The company is expected to be releasing its next quarterly report in 03/13/2023, for which analysts forecasted an EPS of $0.47 while estimate for next year EPS is -$2.13. For MRNS, analysts are forecasting an EPS-growth rate of 20.80% for current year and estimate for EPS growth in next year is -77.00%. In next quarter, company is expected to be making quarterly sales of $4.41 million as analysts are expecting the sales for current fiscal year at $49.88 million and seeing the company making $31.37 million in sales next year. Moreover, analysts are in estimates of $29.48 million for current-quarter revenue.
Currently, Marinus Pharmaceuticals Inc.’s total number of outstanding shares is 47.72M with 0.59% of that held by the insiders while 79.00% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -107.70% and return on equity (ROE) at -12.70%. Stock’s beta reads 1.10. Stock has a price to book (P/B) ratio of 2.15 while price to sale or P/S ratio amounts to 10.97. Its return on asset (ROA) is -3.60% on average.